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Summary Clinical decision-making in advanced cancer is a highly complex process. Many factors are thought to influence this process -
arguably the most important of these is the patient's own preference. Studies show that most patients want to be fully informed as to their
diagnosis and involved in clinical decision-making. However, the attitudes of healthcare workers often preclude patient involvement. Studies
have also shown that acceptability of chemotherapy for minimal therapeutic gain differs markedly between patients depending on factors such
as age, gender and family status. It is clearly impossible to make decisions about what is best for patients without involving them in the
decision-making process. Indeed, it could be argued that active patient participation actually simplifies this process.
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Clinical decision-making in advanced cancer can be very compli-
cated as it is often unclear as to whether the burdens of various
therapeutic options outweigh their benefits. In advanced cancer
the probability ofcure is very low and therefore it can be difficult
tojustify intensive and toxic treatments to achieve palliation. This
is in direct contrast to the situation when the patient has a poten-
tially curable cancer and treatment with intensive and toxic treat-
ments can be readily justified. Nevertheless, in some cancers,
such as advanced colorectal cancer, there is evidence to indicate
that chemotherapy may provide overall benefit to the patient
(Nordic Gastrointestinal Tumor Adjuvant Therapy Group, 1992;
Scheithauer et al, 1993; Allen-Mersh et al, 1994; Glimelius et al,
1995) Despite this evidence, the likelihood of being referred for
palliative chemotherapy varies widely between countries and
areas of clinical expertise. A proportion of physicians remain
ambivalent about the benefits ofpalliative chemotherapy, even in
those cancers in which chemotherapy may offer improved quality
of life with modest increases in a patient's life expectancy
(Taylor, 1996). Undoubtedly, palliative chemotherapy can be
burdensome for the patient as it is associated with a range ofside-
effects and can cause psychological distress, social isolation,
financial difficulties and prolonged hospital stays. These factors
need to be considered when making a decision about how best to
treat a patient with advanced cancer. The 'right' decision will
only be arrived at if a number of factors are considered including
the patient's ability to withstand chemotherapy, attitude towards
chemotherapy and willingness to accept the risk of the potential
trade-off of quality vs quantity of life. Ultimately, the decision
about which treatment to opt for lies primarily with the patient.
Unfortunately, there are many factors that impinge on a patient's
ability to make a decision. This paper seeks to discuss these
factors and to highlight ways in which the decision-making
process can be optimized.
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PATIENTS' PREFERENCES FOR INFORMATION
AND PARTICIPATION
It is generally acknowledged that cancer patients have the right to
participate actively in decisions about their own treatment. A
prerequisite for participation in decision-making is that patients are
provided with sufficient information about their disease and avail-
able treatments. Some people fearthat providing patients with such
information may highlight for them the advanced nature of their
disease and thereby induce a degree of anxiety and despair.
However, a number of studies have showed that cancer patients
generally wish to be involved in decisions that affecttheir treatment
(Cassileth etal, 1980; Blanchard et al, 1988; Sutherland et al, 1989;
Rothenbacher et al, 1997). In the study by Cassileth et al (1980)
patients were asked about their preferences for r(ceiving informa-
tion and participation in the decision-makin process. Most
patients preferred to be involved in decision-mal ng and wanted to
receive information about their condition, alt ough there were
significant differences between age groups (Table 1). Interestingly,
those patients who wanted to be involved in the treatment process
were generally more optimistic than others. Rothenbacher et al
(1997) explored the extent to which hospitalized patients with
advanced cancer wanted to be involved in the process of making
treatment decisions and found that the majority ofpatients wanted
to decide themselves/mainly by themselves (9%) or to collaborate
and decide together with their physician (79%). Physicians in this
study were unaware oftheir patients' preferences. These data may
allay fears that the full provision ofinformation is demoralizing for
cancer patients. Indeed active participation may actually reduce the
burden of treatment, as giving patients the opportunity to express
their own personal preferences allows them to exercise some
control over the situation (Fallowfield et al, 1990). Furthermore, in
an area where it is difficult to balance the benefits oftreatment with
the associated risks, increasing patient involvement may facilitate
the decision-making process.
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Despite the fact that this information has been available for many
years, a survey of European gastroenterologists demonstrated that
patients are frequently not consulted regarding their treatment and,
furthermore, may notbefully informedoftheirdiagnosis (0stergaard
Thomsen et al, 1993). Indeed, 59% (148/252) ofphysicians indicated
thatthey would notinformthepatientthatthey hadcancerwhile 82%
would not tell the patient that their condition was incurable. In
contrast, the majority of physicians would tell the spouse the diag-
nosis and prognosis of the condition. Interestingly, there was a
considerable north-south divide in the attitude of physicians to
keeping thepatientfully informed, probablyreflecting cultural differ-
ences. Physicians in southem Europe were much less likely to tell
theirpatients their diagnosis than those in northern Europe. Clearly, if
patients are to become involved in decision-making they must be
adequately informed about the treatment options. Unfortunately, a
considerable numberofhealthcare professionals lackthe skills neces-
sary to convey information in an open and understandable way,
particularly when prognosis is poor (Grahn, 1996).
ATTITUDES TOWARDS CHEMOTHERAPY
Although palliative chemotherapy may offer improved quality of
life, both the general public and health professionals appear to
hold very negative attitudes towards this therapeutic option
(Slevin et al, 1990; Coiner and Wilson-Barnett, 1992; Bremnes et
al, 1995). This attitude possibly arises from the lack ofinformation
on the physical and psychosocial impact of chemotherapy on the
patient. Response rates are usually measured in terms ofreduction
in tumour size, cure rates, duration of survival and duration of
remission. For the treatment of advanced cancer, however, these
parameters are unlikely to be the most appropriate measures of
treatment benefit. The negative attitude towards palliative
chemotherapy may be one of the reasons why many patients with
advanced cancer are not referred to tertiary centres and rarely
receive treatment at secondary-care centres (Taylor, 1996).
These attitudes are in direct contrast with the results of two
surveys (Slevin et al, 1990; Bremnes et al, 1995) that indicate that
patients may be willing to accept chemotherapy for only minimal
benefit. In the first of these surveys, 100 healthy individuals, 100
cancer patients, 60 oncologists, 85 radiotherapists, 790 general
practitioners and 303 cancer nurses were presented with two hypo-
thetical chemotherapy regimens: the first, a mild regimen with few
side-effects and infrequent hospital visits, and the second, an
intensive regimen with many side-effects and regular hospitaliza-
tion. The participants were asked if they would accept either
regimen if there was a chance of cure, prolongation of life by
3 months or palliation. There was a marked difference in the
response of patients compared with healthcare professionals. For
example, to prolong life by 3 months, 42% of cancer patients
would accept intensive treatment compared with 10% of healthy
individuals, 6% ofcancer nurses, 3% ofgeneral practitioners, 10%
ofoncologists and 0% ofradiotherapists (Slevin et al, 1990).
Table 1 Information and participation preferences among cancer patients
(Cassileth et al, 1980)
Patients (%) P-value
(n = 256)
Age (years) 20-39 40-59 60+
Participation preferences
Prefer participating in decisions 87 62 51
<0.001
Prefer leaving decisions to physician 13 38 49
Type ofinformation desired
Want all information - good or bad 96 79 80
<0.05
Want only minimal or good information 4 21 20
Preferences fordetailedinformation
Prefer minimum 15 40 31
<0.01
Prefer maximum 85 60 69
A more recent survey (Bremnes et al, 1995) asked patients, oncol-
ogists, surgeons, oncology nurses and surgical nurses what, in terms
of a chance of cure, would make toxic chemotherapy acceptable.
Although cancer patients wanted the highest chance of cure for
chemotherapy to be acceptable (Table 2), opinion differed between
patients depending on age and gender. For example, patients
refusing chemotherapy under any circumstances were older and
usually had no children orchildren overthe age of35 years. Patients
aged less than 40 years were willing to accept chemotherapy with
only a small (7%) chance ofcure. Female patients were less likely to
accept intensive toxic therapy than male patients, with cure rates of
50% and 25%, respectively, being demanded.
These data show that health professionals cannot make assump-
tions about an individual patient's attitude to treatment because
opinions may differ markedly between patients. In particular,
younger patients and those with families are much more likely to
accept intensive chemotherapy for only limited clinical benefit.
QUALITY VS QUANTITY OF LIFE
Several studies have investigated whether patients are willing to
trade quality for quantity of life (McNeil et al, 1978, 1981;
O'Connor, 1989; Stiggelbout et al, 1996). These studies showed
some patients to be unwilling to take the risk of death from short-
term complications of treatment. Other patients were willing to
accept a decrease in survival for an improvement in quality of life
(i.e. life in the short term was more important than life in the long
term). This was particularly apparent in older patients (Stiggelbout
et al, 1996). However, other patients would choose the treatment
option giving them the greatest chance of survival. These trade-
offs are exemplified in a study of healthy volunteers (fire-fighters
Table 2 Median scores representing the minimal benefit to make a hypothetical and toxic chemotherapy treatment acceptable (Bremnes et al, 1995)
Surgical nurses Surgeons Oncology nurses Oncologists Controls Patients
(n = 66) (n = 35) (n = 32) (n = 44) (n = 42) (n = 89)
Chance of cure (%) 40 25 25 10 20 43
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and upper and middle management executives) who were asked
whether they would choose a laryngectomy orradiotherapy ifthey
were diagnosed with stage T3 laryngeal cancer. The subjects were
generally found to be more willing to accept radiotherapy and
some reduction in life expectancy than risk loss of speech, smell
and taste after laryngectomy (McNeil et al, 1981). Despite the
artificiality of this situation, it is important to acknowledge that
individuals have different attitudes towards quality and quantity of
life. Willingness to trade-off quality against quantity of life is
clearly a personal decision that health professionals cannot make
for their patients. If a health professional assumes a paternalistic
attitude in this situation, there is a danger that an incorrect decision
will be made. In order to avoid such errors, health professionals
should seek to include patients in the decision-making process.
PATIENT PREFERENCES IN ADVANCED
COLORECTAL CANCER
Ability to manage the side-effects ofcytotoxic drugs and the devel-
opment of newer agents with improved tolerability and more
convenient dosage regimens may in future shift the balance in
favour ofchemotherapy for advanced cancer (Redmond, 1998). In
a recent study of 45 patients with advanced colorectal cancer,
patients were asked to compare four different chemotherapy regi-
mens while taking into consideration several different factors asso-
ciated with treatment by the different regimens (Topham, 1997).
The treatment regimens used were 5-fluorouracil (5-FU) plus
leucovorin on 5 consecutive days every 4 weeks (Mayo regimen);
5-FU plus leucovorin on 2 consecutive days every 2 weeks (de
Gramont regimen); continuous 5-FU infusion via Hickman line for
the duration of treatment; or raltitrexed ('Tomudex') as a single
15-min infusion every 3 weeks. In this study, treatments were not
chosen by name, but an unnamed description of each was given.
More than 80% ofpatients stated apreference for the 3-weekly (i.e.
raltitrexed) regimen. The primary reason for this preference was
the impact that the other treatment regimens had on the patients'
lifestyles. Forexample, the frequent hospitalization associated with
5-FU treatment regimens caused considerable inconvenience for
patients. The continuous infusion regimen was the least popular
option because of the indwelling Hickman line which, for some
patients, was extremely burdensome.
Although the study by Topham (1997) involved only a small
number of patients, it does indicate the importance patients place
on the type of treatment they receive. A further study is currently
under development to investigate patient preferences in the treat-
ment of advanced colorectal cancer. In this study, data from two
large randomized trials using the Mayo regimen and raltitrexed
will be compared. The study will assess the impact of seven clini-
cally important side-effects on patients and the impact of the
administration schedules. Combining this information will allow
the treatment regimens to be rated. It is anticipated that this study
will provide additional information on the aspects of treatment
regimens that have most impact on patients' lives.
In conclusion, patients have a fundamental right to participate in
their care. Patients cannot be considered as a homogeneous group
and health professionals do not always 'know best'. Data show
that not only do patients' opinions regarding treatment frequently
differ from those of health professionals, but that they also differ
between patients. Priorities of quantity vs quality of life must be
considered on an individual basis, taking into consideration the
views of the patient. Individual patient choice must always be
paramount.
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